ValuentumAd

Official PayPal Seal
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Latest Valuentum Commentary

Oct 21, 2015
Valeant Crushed by “Short-Seller” Research Report
Additional uncertainty has surfaced around the biotech firm. We can’t say we are surprised, but the company’s share-price decline has been a monumental one. Despite Valeant’s strong reported performance in recent quarters, the Valuentum Buying Index kept us away from such a risky stock. Please understand why paying attention to the information contained in prices is an important component to any value-, growth- or income-based strategy.
Oct 6, 2015
Attention to Pricing Issues Pressures Valeant
Along with the biotech industry as a whole, Valeant Pharmaceuticals has been the subject of negative publicity lately, and its shares have paid the price.
Sep 28, 2015
Biotechs Bruised
If one is gambling on the drugs of the future, then one must also deal with the uncertainties of the present. Regulatory risk has taken the air out of the biotech space.
Jul 23, 2015
Guide to Second Quarter Earnings; Big Pharma Experiencing Earnings Momentum
Abbott, Bristol-Myers, Celgene, Eli Lilly, Novartis, Roche, Valeant…
Jul 14, 2015
Jan 5, 2015
4 Opportunistic Stocks To Consider Buying in 2015
The Valuentum Buying Index has registered a high rating in the past on these four investment ideas. 2015 may mark strong gains for these gems.
Apr 22, 2014
Big News in Big Pharma
Pfizer is looking to scoop up AstraZeneca, Valeant and Ackman eye Allergan, Eli Lilly and Novartis strike a deal in animal health, and Novartis picks up GSK’s oncology portfolio.
Jan 7, 2014
In-Line Is Good Enough…for Today
Valeant Pharma issues in-line guidance for 2014, while Cray reiterates outlook. Shares of both companies soar.
Nov 22, 2013
Merger Rumors Helping Best Ideas Portfolio Holdings
Best Ideas portfolio holdings DirecTV and Teva Pharma are getting a boost thanks to the rumor mill.
May 30, 2013
Two Huge Deals as M&A Accelerates
Smithfield sells itself and Valeant makes another splash in M&A.


Latest News and Media
The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.